Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000017.xml
Exp Clin Endocrinol Diabetes 1989; 93(2/03): 114-124
DOI: 10.1055/s-0029-1210844
DOI: 10.1055/s-0029-1210844
Original
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Current Stage of Interleukin 2 Receptor Targeted Therapy1)
1) Supported in part by Deutsche Forschungsgemeinschaft (Di 152/8—3, Di 152/8—4) and by NIH Grant 5 RO1 AI 19071-13, Grant- in -Aid #861424 from the American Heart Association and Sandoz Inc.Further Information
Publication History
1988
Publication Date:
16 July 2009 (online)
Summary
The overview summarizes a new and selective form of immunosuppressive therapy by using anti-Interleukin-2 receptor monoclonal antibodies, which may soon become an important form of recipient treatment in organ/tissue transplantation or/and of patient treatment with autoimmune diseases.
Key Words
Interleukin 2 receptor - Monoclonal antibodies - Immunotherapy